159 related articles for article (PubMed ID: 22659283)
21. The individual or combinational effects of Hesperetin and Letrozole on the activity and expression of aromatase in MCF-7 cells.
Rahideh ST; Shidfar F; Nourbakhsh M; Hoseini M; Koohdani F; Entezam M; Keramatipour M
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):38-43. PubMed ID: 27262800
[TBL] [Abstract][Full Text] [Related]
22. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
[TBL] [Abstract][Full Text] [Related]
23. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
[TBL] [Abstract][Full Text] [Related]
24. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
25. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.
Rahideh ST; Keramatipour M; Nourbakhsh M; Koohdani F; Hoseini M; Talebi S; Shidfar F
Biochem Cell Biol; 2017 Aug; 95(4):468-473. PubMed ID: 28177754
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
28. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Liu Y; Zhang X; Liu J; Hou G; Zhang S; Zhang J
Tumour Biol; 2014 Feb; 35(2):1275-86. PubMed ID: 24014089
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
30. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
31. Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.
Dave N; Chow LM; Gudelsky GA; LaSance K; Qi X; Desai PB
Mol Cancer Ther; 2015 Apr; 14(4):857-64. PubMed ID: 25695958
[TBL] [Abstract][Full Text] [Related]
32. The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
Rahideh ST; Keramatipour M; Nourbakhsh M; Koohdani F; Hoseini M; Shidfar F
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):9-13. PubMed ID: 28364779
[TBL] [Abstract][Full Text] [Related]
33. Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
Sendur MA; Aksoy S; Ozdemir NY; Akinci MB; Zengin N; Altundag K
Asian Pac J Cancer Prev; 2013; 14(1):607-8. PubMed ID: 23534804
[No Abstract] [Full Text] [Related]
34. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
[TBL] [Abstract][Full Text] [Related]
35. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Surmeli Z; Gursoy P; Erdogan AP; Bozkurt E; Atmaca H; Uzunoglu S; Sezgin C; Şanlı UA; Uslu R; Karaca B
Tumour Biol; 2016 Mar; 37(3):3665-73. PubMed ID: 26462835
[TBL] [Abstract][Full Text] [Related]
36. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom HP; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N
Ann Oncol; 2013 Feb; 24(2):398-405. PubMed ID: 23047045
[TBL] [Abstract][Full Text] [Related]
37. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
38. Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents.
Diaz de Greñu B; Fernández-Aroca DM; Organero JA; Durá G; Jalón FA; Sánchez-Prieto R; Ruiz-Hidalgo MJ; Rodríguez AM; Santos L; Albasanz JL; Manzano BR
J Biol Inorg Chem; 2023 Sep; 28(6):531-547. PubMed ID: 37458856
[TBL] [Abstract][Full Text] [Related]
39. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
40. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
